DelveInsight’s “Essential Thrombocythemia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Essential Thrombocythemia, historical and forecasted epidemiology as well as the Essential Thrombocythemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Essential Thrombocythemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Essential Thrombocythemia Market Forecast

Some of the key facts of the Essential Thrombocythemia Market Report:

• The Essential Thrombocythemia market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

• In June 2025, Incyte (Nasdaq: INCY) announced initial clinical results from two studies assessing the safety, tolerability, and efficacy of INCA033989, a novel first-in-class targeted monoclonal antibody discovered by Incyte, in patients with mutant calreticulin (mutCALR)-positive myeloproliferative neoplasms (MPNs). These findings, presented in the Late-Breaking Oral Session (#LB4002) at the European Hematology Association 2025 (EHA2025) Congress in Milan, Italy, highlight the dose escalation phase in patients with high-risk essential thrombocythemia (ET) who are resistant or intolerant to previous cytoreductive treatments.

• In January 2025, The SURPASS-ET trial (NCT04285086) evaluating ropeginterferon alfa-2b-njft (P1101; Besremi) in patients with essential thrombocythemia (ET) successfully met its primary endpoint, demonstrating durable clinical responses based on modified European LeukemiaNet (ELN) criteria. In the intent-to-treat (ITT) population, 42.9% (39/91) of patients receiving ropeginterferon alfa-2b achieved durable responses at 9 and 12 months, compared to 6.0% (5/83) of patients in the comparator group treated with anagrelide (Agrylin) (P = .0001).

• A study by Thompson et al. estimated the prevalence of Essential Thrombocythemia (ET). This research involved 237 patients and found an estimated prevalence of approximately 18 cases per 100,000 per year.

• In France, there are approximately 1 to 2.5 new cases per 100,000 inhabitants each year. Additionally, the prevalence is around 1 case per 3,330 people.

• A study by Harrison et al. estimated the distribution of ET patients by risk category. Low-risk patients made up about 22% of cases, intermediate-risk patients accounted for 16%, and high-risk patients comprised 20%. Additionally, around 42% of patients were not classified at the time of diagnosis.

• Key Essential Thrombocythemia Companies: Jubilant Therapeutics Inc, Kartos Therapeutics, Inc, Imago BioSciences,Inc., MorphoSys AG, PharmaEssentia Corporation, Incyte Corporation, Karyopharm Therapeutics Inc, Novartis, PharmaEssentia, CTI BioPharma, Celgene, NS Pharma, Inc., Kartos Therapeutics, Inc., Sierra Oncology LLC, GlaxoSmithKline, Incyte Corporation, Imago BioSciences, and others

• Key Essential Thrombocythemia Therapies: JBI-802, Navtemadlin + TL-895, Bomedemstat, Pelabresib, P1101, IMG-7289, Ruxolitinib, Selinexor, Reparixin, Ropeginterferon alfa-2b, Pacritinib, FEDRATINIB, NS-018, KRT-232, Momelotinib, MMB, INCB000928, Bomedemstat, and others

• The Essential Thrombocythemia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Essential Thrombocythemia pipeline products will significantly revolutionize the Essential Thrombocythemia market dynamics.

Essential Thrombocythemia Overview

Essential thrombocythemia is a chronic blood disorder characterized by the overproduction of platelets (thrombocytes) by the bone marrow. Platelets are essential for blood clotting, but in ET, their excessive number can lead to an increased risk of abnormal blood clot formation (thrombosis), bleeding complications, or both.

Get a Free sample for the Essential Thrombocythemia Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/essential-thrombocythemia-et-market-insights

Essential Thrombocythemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Essential Thrombocythemia Epidemiology Segmentation:

The Essential Thrombocythemia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Essential Thrombocythemia

• Prevalent Cases of Essential Thrombocythemia by severity

• Gender-specific Prevalence of Essential Thrombocythemia

• Diagnosed Cases of Episodic and Chronic Essential Thrombocythemia

Download the report to understand which factors are driving Essential Thrombocythemia epidemiology trends @ Essential Thrombocythemia Epidemiology Forecast

Essential Thrombocythemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Essential Thrombocythemia market or expected to get launched during the study period. The analysis covers Essential Thrombocythemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Essential Thrombocythemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Essential Thrombocythemia Therapies and Key Companies

• JBI-802: Jubilant Therapeutics Inc

• Navtemadlin + TL-895: Kartos Therapeutics, Inc

• Bomedemstat: Imago BioSciences,Inc.

• Pelabresib: MorphoSys AG

• P1101: PharmaEssentia Corporation

• IMG-7289: Imago BioSciences, Inc

• Ruxolitinib: Incyte Corporation

• Selinexor: Karyopharm Therapeutics Inc

• Reparixin: Novartis

• Ropeginterferon alfa-2b: PharmaEssentia

• Pacritinib: CTI BioPharma

• FEDRATINIB: Celgene

• NS-018: NS Pharma, Inc.

• KRT-232: Kartos Therapeutics, Inc.

• Momelotinib: Sierra Oncology LLC

• MMB: GlaxoSmithKline

• INCB000928: Incyte Corporation

• Bomedemstat: Imago BioSciences

Discover more about therapies set to grab major Essential Thrombocythemia market share @ Essential Thrombocythemia Treatment Landscape

Essential Thrombocythemia Market Strengths

• The World Health Organization (WHO) revised the criteria for diagnosing ET in 2016, providing clear guidelines for identification.

• The revised-IPSET-t classification helps stratify thrombotic risk, aiding in treatment decisions.

Essential Thrombocythemia Market Opportunities

• Ongoing research aims to identify disease-modifying drugs that can prevent progression to more aggressive myeloid neoplasms, especially in younger patients.

• As understanding of ET improves, novel therapies may emerge to enhance patient outcomes.

Scope of the Essential Thrombocythemia Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Essential Thrombocythemia Companies: Jubilant Therapeutics Inc, Kartos Therapeutics, Inc, Imago BioSciences,Inc., MorphoSys AG, PharmaEssentia Corporation, Incyte Corporation, Karyopharm Therapeutics Inc, Novartis, PharmaEssentia, CTI BioPharma, Celgene, NS Pharma, Inc., Kartos Therapeutics, Inc., Sierra Oncology LLC, GlaxoSmithKline, Incyte Corporation, Imago BioSciences, and others

• Key Essential Thrombocythemia Therapies: JBI-802, Navtemadlin + TL-895, Bomedemstat, Pelabresib, P1101, IMG-7289, Ruxolitinib, Selinexor, Reparixin, Ropeginterferon alfa-2b, Pacritinib, FEDRATINIB, NS-018, KRT-232, Momelotinib, MMB, INCB000928, Bomedemstat, and others

• Essential Thrombocythemia Therapeutic Assessment: Essential Thrombocythemia current marketed and Essential Thrombocythemia emerging therapies

• Essential Thrombocythemia Market Dynamics: Essential Thrombocythemia market drivers and Essential Thrombocythemia market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Essential Thrombocythemia Unmet Needs, KOL’s views, Analyst’s views, Essential Thrombocythemia Market Access and Reimbursement

To know more about Essential Thrombocythemia companies working in the treatment market, visit @ Essential Thrombocythemia Clinical Trials and Therapeutic Assessment

Table of Contents

1. Essential Thrombocythemia Market Report Introduction

2. Executive Summary for Essential Thrombocythemia

3. SWOT analysis of Essential Thrombocythemia

4. Essential Thrombocythemia Patient Share (%) Overview at a Glance

5. Essential Thrombocythemia Market Overview at a Glance

6. Essential Thrombocythemia Disease Background and Overview

7. Essential Thrombocythemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Essential Thrombocythemia

9. Essential Thrombocythemia Current Treatment and Medical Practices

10. Essential Thrombocythemia Unmet Needs

11. Essential Thrombocythemia Emerging Therapies

12. Essential Thrombocythemia Market Outlook

13. Country-Wise Essential Thrombocythemia Market Analysis (2020–2034)

14. Essential Thrombocythemia Market Access and Reimbursement of Therapies

15. Essential Thrombocythemia Market Drivers

16. Essential Thrombocythemia Market Barriers

17. Essential Thrombocythemia Appendix

18. Essential Thrombocythemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/